<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680138</article-id><article-id pub-id-type="doi">10.3390/v16121855</article-id><article-id pub-id-type="publisher-id">viruses-16-01855</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Preparation of Phage Display cDNA Libraries for Identifying Immunogenic Tumor Antigens: Challenges in Functional cDNA Presentation and Approaches to Overcoming Them</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bri&#x00161;ar</surname><given-names>Nu&#x00161;a</given-names></name><xref rid="af1-viruses-16-01855" ref-type="aff">1</xref><xref rid="af2-viruses-16-01855" ref-type="aff">2</xref><xref rid="c1-viruses-16-01855" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9650-9431</contrib-id><name><surname>&#x00160;uster</surname><given-names>Katja</given-names></name><xref rid="af3-viruses-16-01855" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>C&#x000f6;r</surname><given-names>Andrej</given-names></name><xref rid="af3-viruses-16-01855" ref-type="aff">3</xref><xref rid="af4-viruses-16-01855" ref-type="aff">4</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Skurnik</surname><given-names>Mikael</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-16-01855"><label>1</label>Faculty of Health Sciences, University of Primorska, 6310 Izola, Slovenia</aff><aff id="af2-viruses-16-01855"><label>2</label>Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia</aff><aff id="af3-viruses-16-01855"><label>3</label>Valdoltra Orthopaedic Hospital, 6280 Ankaran, Slovenia; <email>katja.suster@ob-valdoltra.si</email> (K.&#x00160;.); <email>andrej.coer@ob-valdoltra.si</email> (A.C.)</aff><aff id="af4-viruses-16-01855"><label>4</label>Faculty of Education, University of Primorska, 6310 Izola, Slovenia</aff><author-notes><corresp id="c1-viruses-16-01855"><label>*</label>Correspondence: <email>nusa.brisar@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>16</volume><issue>12</issue><elocation-id>1855</elocation-id><history><date date-type="received"><day>26</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>25</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>27</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Cancer continues to represent a substantial burden in terms of its morbidity and mortality, underscoring the imperative for the development of novel and efficacious treatment modalities. Recent advances in cancer immunotherapy have highlighted the importance of identifying tumour-specific antigens, which can assist the immune system in targeting malignant cells effectively. Phage display technology has emerged as an effective tool for the discovery of novel antigens through cDNA library screening, representing a significant advancement in the field of immunological research. This review examines the discovery of tumour antigens using phage display technology, emphasising the construction of cDNA libraries, their subsequent display on bacteriophages and the utilisation of diverse biopanning techniques. These elements play a pivotal role in advancing the discovery of novel tumour antigens and the development of targeted cancer therapies. This review addresses the challenges associated with the filamentous phage display of cDNA libraries and proposes strategies to improve the effectiveness of this approach, encouraging further research for clinical applications.</p></abstract><kwd-group><kwd>nanoparticles</kwd><kwd>phage display technology</kwd><kwd>filamentous bacteriophages</kwd><kwd>cDNA libraries</kwd><kwd>tumor antigens</kwd><kwd>biopanning</kwd><kwd>immunotherapy</kwd></kwd-group><funding-group><award-group><funding-source>Slovenian Research and Innovation Agency</funding-source><award-id>P3-0003, 56962-1988-2413</award-id></award-group><funding-statement>This research was funded by the Slovenian Research and Innovation Agency, P3-0003, 56962-1988-2413.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-16-01855"><title>1. Introduction</title><p>Despite remarkable medical advancements, cancer remains the second leading cause of morbidity and mortality worldwide. For years, the cornerstones of cancer treatment have been surgery, chemotherapy and radiation therapy [<xref rid="B1-viruses-16-01855" ref-type="bibr">1</xref>]. However, continued progress in the understanding of the biology and molecular background of several types of malignancies has resulted in the development of advanced cancer immunotherapies that harness the natural mechanisms of the immune system to recognise and eliminate malignant cells [<xref rid="B2-viruses-16-01855" ref-type="bibr">2</xref>].</p><p>When normal cells undergo malignant transformation, they acquire tumorigenic genetic alterations that cause changes in the protein structure or the timing or quantity of protein expression [<xref rid="B3-viruses-16-01855" ref-type="bibr">3</xref>]. The immune system can often recognise these altered tumour proteins (i.e., antigens) as non-self-proteins and subsequently kill tumour cells. Recognition by effector T lymphocytes, crucial cells in the cancer immunity cycle, is possible only when these antigens are presented on the surface of human leukocyte antigen (HLA) molecules [<xref rid="B4-viruses-16-01855" ref-type="bibr">4</xref>]. Therefore, systematic identification of tumour antigens that can be incorporated into treatments that induce T-cell-mediated tumour rejection is indispensable to rapidly advancing the development of several cancer immunotherapies [<xref rid="B5-viruses-16-01855" ref-type="bibr">5</xref>].</p><p>The discovery and characterisation of new antigens are achievable using a diverse range of high-throughput multi-omics analyses, including tandem mass spectrometry (MS/MS) and next-generation sequencing (NGS) or a combination of both [<xref rid="B6-viruses-16-01855" ref-type="bibr">6</xref>,<xref rid="B7-viruses-16-01855" ref-type="bibr">7</xref>]. An indirect method for antigen discovery is also provided by screening cDNA expression libraries (e.g., using sera from cancer patients). Different surface display technologies [<xref rid="B8-viruses-16-01855" ref-type="bibr">8</xref>] enable screening cDNA libraries for peptides that interact with a bait protein and thus the detection of interaction partners with specific desired properties. For this purpose, bacteriophage surface display is by far the most widespread utility [<xref rid="B9-viruses-16-01855" ref-type="bibr">9</xref>,<xref rid="B10-viruses-16-01855" ref-type="bibr">10</xref>,<xref rid="B11-viruses-16-01855" ref-type="bibr">11</xref>,<xref rid="B12-viruses-16-01855" ref-type="bibr">12</xref>].</p><p>Bacteriophages, or phages, are viruses that specifically infect bacteria and subordinate their cellular machinery to create new phage particles, ultimately resulting in the release of new phage virions [<xref rid="B13-viruses-16-01855" ref-type="bibr">13</xref>]. George Smith paved the way for bacteriophage engineering in 1985 when he demonstrated the fusion of (poly)peptides to the outer proteins (i.e., capsid) of phages, enabling surface display [<xref rid="B14-viruses-16-01855" ref-type="bibr">14</xref>]. His work, for which he was awarded the Nobel Prize in 2018, laid the groundwork for the development of phage display technology and biopanning methods [<xref rid="B15-viruses-16-01855" ref-type="bibr">15</xref>].</p><p>Since then, phages have been exploited in many different research fields, among these also their exploitation as target nanocarriers in cancer immunotherapy. In this way, a favourable presentation of tumour antigens to immune cells can be achieved to direct them to act against tumour cells [<xref rid="B16-viruses-16-01855" ref-type="bibr">16</xref>]. Lately, there has been an increase in the research on screening the cDNA expression libraries displayed on the surface of filamentous phages. Cloning a wide repertoire of cDNA libraries prepared from tumour lysates into phages and further selection of (poly)peptides using in situ, in vitro, in vivo and ex vivo screening methods enable the identification of new cancer-specific ligands that could potentially be used as therapeutic targets or biomarkers [<xref rid="B17-viruses-16-01855" ref-type="bibr">17</xref>].</p><p>Despite the latest developments in the field, there are still some limiting challenges in the filamentous phage display of cDNA libraries. Apart from being subjected to the intrinsic biological limitations in phage and bacterial life cycles [<xref rid="B18-viruses-16-01855" ref-type="bibr">18</xref>,<xref rid="B19-viruses-16-01855" ref-type="bibr">19</xref>,<xref rid="B20-viruses-16-01855" ref-type="bibr">20</xref>], the synthesis of fusion proteins is frequently prevented by translational stop codons in reverse-transcribed eukaryotic mRNA [<xref rid="B18-viruses-16-01855" ref-type="bibr">18</xref>], shifts in reading frames or the misorientation of inserted fragments [<xref rid="B21-viruses-16-01855" ref-type="bibr">21</xref>]. However, several strategies exist and can be successfully adopted to overcome these challenges and make cDNA libraries more accessible for phage display.</p><p>This review aims to describe tumour antigen discovery, focusing on recent developments in the use of antigen cDNA libraries and phage display. During this review, we critically expose and discuss key challenges and limitations in the field of filamentous phage display of cDNA libraries and the currently employed solutions and suggest new possible forms of improvement. Outlining the potential of this technique for use in cancer immunotherapy, we expect this review to open new ideas and possibilities for new research regarding advanced cancer treatment.</p></sec><sec id="sec2-viruses-16-01855"><title>2. Filamentous Bacteriophages and Phage Display Technology: An Overview</title><p>Bacteriophages (or phages for short) are a class of prokaryotic viruses abundant in nature and harmless to humans. Although the families of phages greatly vary in their shapes, sizes and life cycles, they uniformly consist of nucleic acids and proteins. The phage genome can come in the form of single-stranded (ss) or double-stranded (ds) DNA or RNA and is encapsulated by a protein capsid [<xref rid="B13-viruses-16-01855" ref-type="bibr">13</xref>]. There are two types of bacteriophages, depending on their mode of replication: virulent (lytic) and lysogenic (lysogenic). Lytic bacteriophages subordinate the bacterial cellular machinery for the replication of bacteriophage genetic material and the synthesis of bacteriophage proteins, resulting in the destruction (lysis) of the bacterium and the release of thousands of new identical bacteriophage virions. Lysogenic bacteriophages incorporate their genome into the bacterial genome, producing a prophage that replicates along with the bacterial DNA as the bacterium replicates. However, a lysogenic bacteriophage can also enter the lytic cycle and start to build new virions [<xref rid="B22-viruses-16-01855" ref-type="bibr">22</xref>]. Phages were independently discovered by Frederick Twort in 1915 and F&#x000e9;lix D&#x02019;Herelle in 1917 for their use against bacterial infections; however, research on this theme was abandoned upon the discovery of antibiotics. It was only in 1985 that bacteriophage research for human therapy came to the fore again [<xref rid="B23-viruses-16-01855" ref-type="bibr">23</xref>]. In fact, with phage display technology, phages began to be used (a) as a platform for displaying tumour antigens for cancer immunotherapy or (b) to uncover novel tumour antigens for the design of new delivery systems [<xref rid="B24-viruses-16-01855" ref-type="bibr">24</xref>].</p><p>In phage display technology, phages can be engineered to present foreign peptides or proteins as a fusion with phage coat proteins. The power of phage display technology is in establishing the link between the genotype (the gene sequence encoding the displayed peptide/protein) and the phenotype (the displayed peptide/protein). A gene sequence encoding a peptide or a protein of interest is inserted into a coat protein gene. Through the inherent phage machinery, a recombinant fusion protein is formed and subsequently incorporated into the phage capsid and displayed on the surface of the phage [<xref rid="B13-viruses-16-01855" ref-type="bibr">13</xref>,<xref rid="B23-viruses-16-01855" ref-type="bibr">23</xref>,<xref rid="B24-viruses-16-01855" ref-type="bibr">24</xref>,<xref rid="B25-viruses-16-01855" ref-type="bibr">25</xref>]. Commonly, phage display employs either phage or phagemid vectors.</p><p>Among these phage vectors are the most widely and successfully exploited filamentous phages of the <italic toggle="yes">Inoviridae</italic> family M13, fd and f1 [<xref rid="B15-viruses-16-01855" ref-type="bibr">15</xref>]. They are peculiarities in the world of phages in terms of their appearance and mode of assembly, as they do not match the archetypal phage head and tail structure and do not lyse bacterial hosts in their life cycles [<xref rid="B20-viruses-16-01855" ref-type="bibr">20</xref>]. In the case of M13 phages, N-terminal fusion of exogenous (poly)peptides to pIII and pVIII and C-terminal fusion to pVI coat proteins proved to be the most effective for the display of cDNA libraries. These differ in the number of (poly)peptides with which the capsid is decorated. PVIII is present in 2700 copies surrounding the whole phage and is preferred for the display of short peptides, while pIII and pVI are expressed in 5 or 4 copies at one end of the phage and are used for the display of larger peptides [<xref rid="B26-viruses-16-01855" ref-type="bibr">26</xref>]. Sometimes, for example, if the size of an insert is very large, such a display may cause slower phage assembly and disrupt the arrangement of the pIII proteins, leading to reduced phage infectivity. In such cases, phagemid systems are preferred, which combine selected genomic features of phages and bacterial plasmids, providing several advantages [<xref rid="B27-viruses-16-01855" ref-type="bibr">27</xref>]. Phagemids are phage-derived vectors that do not encode for all of the functional and structural proteins of the phage, instead carrying only the necessary origins of replication, a cloning cassette, a selective marker and one type of coat protein that is employed for the display [<xref rid="B15-viruses-16-01855" ref-type="bibr">15</xref>]. They contain the plasmid origin of replication allowing for circular dsDNA replication, the filamentous phage origin of replication for allowing ssDNA replication and the phage-packing signal, which allows for the packing of ssDNA into the phage capsids. Accordingly, the phagemid can maintain itself as a plasmid in a bacterial host but is not able to finish the assembly of progeny phage virions independently. Only when bacteria harbours both the phagemid and the helper phage, which contains the genetic elements for the remaining phage coat proteins that are missing in the phagemid, can infective particles with the same morphology as the filamentous phages be produced and released from infected bacteria [<xref rid="B27-viruses-16-01855" ref-type="bibr">27</xref>].</p></sec><sec id="sec3-viruses-16-01855"><title>3. Discovery of Tumor Antigens Using Phage Display Technology</title><sec id="sec3dot1-viruses-16-01855"><title>3.1. Construction of cDNA Libraries and Their Display on Bacteriophages</title><p>The preparation of phage-displayed cDNA library begins to take place with the construction of a cDNA library encoding different peptides/proteins. The first step is the isolation of cytoplasmic RNA from the studied cell or tissue type. Cytoplasmic RNA consists primarily of ribosomal RNA (rRNA), transfer RNA (tRNA) and, to a lesser extent, messenger RNA (mRNA). Further separation of eukaryotic mRNA from the RNA mixture using affinity chromatography is possible due to its unique structure. The 3&#x02032; end of mRNA rich in adenylate residues is referred to as the poly-adenosine (poly-A) tail. With it, the mRNA binds to latex or magnetic particles pre-conjugated with chains of thymidylate (oligo-dT), which is complementary to the poly-A tail. As the cell extract passes through the purification column, only the mRNA base-pairs with oligo-dT; on the contrary, the tRNA and rRNA and other unbound molecules are washed away [<xref rid="B28-viruses-16-01855" ref-type="bibr">28</xref>,<xref rid="B29-viruses-16-01855" ref-type="bibr">29</xref>]. The resulting extract of total cellular mRNA contains many different mRNA molecules encoding different proteins [<xref rid="B29-viruses-16-01855" ref-type="bibr">29</xref>] (<xref rid="viruses-16-01855-f001" ref-type="fig">Figure 1</xref>).</p><p>In the next step, an enzyme reverse transcriptase synthesises cDNAs corresponding to all mRNAs, resulting in mRNA-cDNA duplexes. At the 3&#x02032; end of the mRNA, the bound oligo-dT serves as a primer for the enzyme which extends the 3&#x02032; end of the mRNA [<xref rid="B29-viruses-16-01855" ref-type="bibr">29</xref>]. The yield of cDNA containing the entire coding sequence depends on the quality of the mRNA and the presence of secondary mRNA structures, which reduce the efficiency of the reaction [<xref rid="B28-viruses-16-01855" ref-type="bibr">28</xref>]. When the mRNAs in mRNA-cDNA duplexes are removed, the remaining cDNAs are converted into double-stranded cDNAs by the enzymes terminal transferase and DNA polymerase. The enzyme terminal transferase, which does not need a template for its function, adds several residues of a selected nucleotide (e.g., guanine) to the 3&#x02032; end of the cDNA. A synthetic oligo-dC fragment is then complementarily bound to the 3&#x02032; oligo-dG and serves as a primer for the enzyme DNA polymerase, which synthesises DNA strands complementary to the original cDNAs. Each double-stranded cDNA fragment corresponds to each of the mRNAs in the cell extract [<xref rid="B29-viruses-16-01855" ref-type="bibr">29</xref>] (<xref rid="viruses-16-01855-f001" ref-type="fig">Figure 1</xref>).</p><p>Restriction-cleaved double-stranded cDNA fragments are further cloned into various phage or phagemid vectors. Because cDNA represents a complementary sequence of mRNA, it includes only the exon portions of the gene. Consequently, the amino acid sequence of a peptide/protein displayed on a phage can be determined directly from the nucleotide sequence of its corresponding cDNA variant within the phage genome [<xref rid="B29-viruses-16-01855" ref-type="bibr">29</xref>] (<xref rid="viruses-16-01855-f001" ref-type="fig">Figure 1</xref>).</p><p>A promising strategy in cancer therapy is the use of tumour-targeting peptides to selectively deliver drugs or active agents to solid tumours. Several tumour-homing peptides have been identified through combinatorial library screening, including glioma-targeting peptides, tumour-vasculature-targeting peptides and peptides targeting tumour invasion, as well as cell-penetrating and tumour-penetrating peptides [<xref rid="B30-viruses-16-01855" ref-type="bibr">30</xref>,<xref rid="B31-viruses-16-01855" ref-type="bibr">31</xref>,<xref rid="B32-viruses-16-01855" ref-type="bibr">32</xref>]. In particular, phage display libraries have facilitated the discovery of novel ligands for cancers such as gastric cancer [<xref rid="B33-viruses-16-01855" ref-type="bibr">33</xref>], melanoma [<xref rid="B34-viruses-16-01855" ref-type="bibr">34</xref>] and breast cancer [<xref rid="B35-viruses-16-01855" ref-type="bibr">35</xref>,<xref rid="B36-viruses-16-01855" ref-type="bibr">36</xref>]. This approach has also contributed to the development of numerous phage-derived antibodies, many of which have progressed to clinical trials, leading to the approval of over a dozen therapeutic antibodies [<xref rid="B37-viruses-16-01855" ref-type="bibr">37</xref>].</p></sec><sec id="sec3dot2-viruses-16-01855"><title>3.2. Affinity Selection Strategies for Screening Bacteriophage Display Libraries</title><p>The surface of a phage can be variably decorated with multiple copies of the polypeptide of interest, and within a phage population, a multiplicity of unique motifs are rapidly and easily displayed to create a phage-displayed library [<xref rid="B23-viruses-16-01855" ref-type="bibr">23</xref>]. Through an affinity-driven process, commonly known as biopanning, the phage-displayed libraries are screened against a wide variety of targets, and the target-specific (poly)peptides displayed on the phage (e.g., new cancer ligands) are subsequently identified. In biopanning, the phage display library is first incubated with the target for a defined period of time. This is followed by a series of stringent washing steps. Phages with binding affinity to the desired target molecule (e.g., the bait protein) are retained, while weakly bound or unbound phages are washed away. The interacting phages are then eluted and amplified by re-infecting bacteria, thus creating a new phage library with higher-affinity and specific binders used for a subsequent three to five rounds of panning. Finally, the peptides/proteins with the highest affinity are identified through DNA sequencing of the selected phages [<xref rid="B15-viruses-16-01855" ref-type="bibr">15</xref>,<xref rid="B24-viruses-16-01855" ref-type="bibr">24</xref>,<xref rid="B38-viruses-16-01855" ref-type="bibr">38</xref>] (<xref rid="viruses-16-01855-f002" ref-type="fig">Figure 2</xref>). Applying phage display biopanning techniques enables high-throughput, rapid, cost-effective screening and the selection of phage-displayed peptides/proteins targeting overexpressed tumour cell receptors, as well as components in tumour microenvironment like immune cells exerting pro-tumour activities, tumour vasculature and endothelial cells [<xref rid="B17-viruses-16-01855" ref-type="bibr">17</xref>]. These features have to be evaluated when choosing a platform for new tumour antigen discovery and cancer vaccine design.</p><p>The biopanning procedure can be performed using various approaches. One common method, in situ screening, involves immobilising the purified target molecule onto a solid support [<xref rid="B17-viruses-16-01855" ref-type="bibr">17</xref>,<xref rid="B38-viruses-16-01855" ref-type="bibr">38</xref>]. Despite this being the most straightforward and frequently used method, there are still some shortcomings that need to be considered. When a target molecule is artificially attached to a carrier, its secondary structure may be misrepresented, posing the risk of isolating a phage clone unable to bind or with non-specific binding upon exposure to the in vitro or in vivo system. Biopanning can also be carried out in vitro on cell lines to identify cell-surface-interacting peptides. This approach preserves the biological functions of cells, the proper folding and 3D structure of the proteins, the level of receptor expression and their interaction with other proteins [<xref rid="B17-viruses-16-01855" ref-type="bibr">17</xref>]. The utilisation of both in vitro and in vivo biopanning approaches in phage display technology has facilitated the discovery of peptides with high specificity and affinity which could be employed as therapeutics in drug delivery, diagnostics and tumour targeting [<xref rid="B39-viruses-16-01855" ref-type="bibr">39</xref>]. Ex vivo screening in an isolated sample enables the selection of certain rare cells in a heterogeneous population, and in vivo screening in animals enables the identification of organ- or disease-specific homing peptides [<xref rid="B17-viruses-16-01855" ref-type="bibr">17</xref>,<xref rid="B38-viruses-16-01855" ref-type="bibr">38</xref>]. Yet the risk is that the selected peptides may not be useful for human treatment due to differences in the peptide binding between different species [<xref rid="B17-viruses-16-01855" ref-type="bibr">17</xref>]. The half-life of administered phages is also questionable [<xref rid="B40-viruses-16-01855" ref-type="bibr">40</xref>]. To overcome these hindrances, screening libraries in vivo in patients in the terminal stage of cancer allows for better mimicry of natural heterogeneous cells or the conditions of the human body [<xref rid="B41-viruses-16-01855" ref-type="bibr">41</xref>] (<xref rid="viruses-16-01855-f002" ref-type="fig">Figure 2</xref>).</p></sec></sec><sec id="sec4-viruses-16-01855"><title>4. Phage Display of cDNA Libraries: Challenges in Functional cDNA Presentation and Employed Solutions</title><p>Phage coat proteins are synthetised in the controlled and reducing environment of the bacterial cytoplasm and are translocated across the inner membrane into the oxidising environment of the periplasm. Minor coat proteins pVI, pVII and pIX are synthesised without signal peptides, whereas pIII and major protein pVIII are synthesised with an amino terminal signal peptide which directs their insertion into the cytoplasmic membrane, where they reside before being assembled into a new phage virion. Any peptide/protein fused to the periplasmic portion of these phage proteins theoretically should be likely to be packed into a phage virion, provided it can be translocated efficiently into the membrane and fold properly, escape degradation in the periplasm and not interfere with the process that happens at the assembly site [<xref rid="B42-viruses-16-01855" ref-type="bibr">42</xref>].</p><p>The wide range of peptides and proteins that can be expressed on the surface of filamentous phages is truly incredible. One must be aware, however, that not each and every peptide or protein can be packed into the phage capsid [<xref rid="B42-viruses-16-01855" ref-type="bibr">42</xref>]. Especially when working with the diverse nature of cDNA libraries, the success of their display is influenced by the protein&#x02019;s length, folding characteristics, stability and possible toxicity to the bacterial host [<xref rid="B43-viruses-16-01855" ref-type="bibr">43</xref>]. The synthesis of fusion proteins, as well as the assembly of the phage virion, is determined by the bacterial physiology [<xref rid="B42-viruses-16-01855" ref-type="bibr">42</xref>].</p><p>Accordingly, the display of cDNA libraries on phages is thus biased towards naturally secreted proteins, e.g., tumour antigens that efficiently pass through the <italic toggle="yes">E. coli</italic> translocation machinery. By contrast, the display of proteins that are less compatible with the mechanisms of phage assembly or physiological characteristics of <italic toggle="yes">E. coli</italic>, e.g., nuclear, cytoplasmic and transmembrane proteins (receptors, cell wall proteins and proteins embedded into the membrane bilayer), is hampered [<xref rid="B18-viruses-16-01855" ref-type="bibr">18</xref>,<xref rid="B44-viruses-16-01855" ref-type="bibr">44</xref>]. Protein fusions with sequences that do not normally cross the membrane, e.g., long stretches of hydrophobic residues that act as transmembrane stop transfer regions, also restrain the display of such cDNA gene products on phages. Equally, membrane translocation represents a drawback for large fusion proteins and thus limits the size of the DNA inserts in the phage genome. The upper limit for the size of fusion protein would be, as expected, limited by the 7 nm pIV exit pore [<xref rid="B42-viruses-16-01855" ref-type="bibr">42</xref>]. So far, proteins up to 86 kDa have been functionally displayed [<xref rid="B18-viruses-16-01855" ref-type="bibr">18</xref>].</p><p>Various measures have been developed to overcome these challenges described. Different signal peptides have been used to allow translocation into the periplasm [<xref rid="B45-viruses-16-01855" ref-type="bibr">45</xref>], the folding of fusion proteins in the periplasm was improved by chaperone co-expression [<xref rid="B46-viruses-16-01855" ref-type="bibr">46</xref>] and genetically engineered protease-deficient bacterial strains have shown a decreased rate of degradation of fusion proteins [<xref rid="B42-viruses-16-01855" ref-type="bibr">42</xref>]. Also, employing different secretory pathways of <italic toggle="yes">E. coli</italic> enables the translocation of fusion proteins across the membrane prior to phage assembly. To date, four mechanisms have been identified in <italic toggle="yes">E. coli</italic>, with the Sec, SRP and Tat pathways requiring specific proteins for the translocation process and the fourth mechanism termed the spontaneous insertion pathway. The majority of the proteins displayed are post-translationally targeted to the membrane in an unfolded state by the Sec system, especially antibodies that require the oxidative periplasm environment for folding. To the contrary, the Tat pathway translocates folded proteins that contain metal or other cofactors and requires the reducing environment of the cytoplasm for proper folding and activity [<xref rid="B19-viruses-16-01855" ref-type="bibr">19</xref>].</p><p>It is quite amazing how versatile, widely utilised and flexible the filamentous phage display system is, in light of all the possible constraints that the process of protein translocation and phage assembly might place on it. Beyond this, there are also technical issues that pose challenges when fusing cDNA to pIII or pVIII coat proteins. The integrity of the C-terminal end of pIII/pVIII is essential for efficient phage assembly; consequently, fusion of peptides/proteins is possible at the N-terminal end of pIII/pVIII. However, N-terminal fusion of full-length cDNA libraries is challenging due to the translational stop codon located at the 3&#x02032; end of the reverse-transcribed eukaryotic mRNA, which prevents the synthesis of fusion proteins [<xref rid="B18-viruses-16-01855" ref-type="bibr">18</xref>,<xref rid="B43-viruses-16-01855" ref-type="bibr">43</xref>]. Furthermore, the cDNA and leader sequence must be in the same reading frame as the pIII/pVIII gene. Since most clones contain non-functional inserts due to shifts in the reading frame or the misorientation of inserted fragments, this hinders the use of the cDNA libraries displayed on the phage [<xref rid="B43-viruses-16-01855" ref-type="bibr">43</xref>].</p><p>The cloning strategies employed for functional phage display of cDNA libraries are represented by (a) the indirect display of peptides/proteins on the phage by means of a leucine zipper structure; (b) peptide/protein fusion to the C-terminal end of the pVI coat protein; and (c) the fragmentation of the cDNA and selection of open reading frames prior to cloning into the phage vector.</p><sec id="sec4dot1-viruses-16-01855"><title>4.1. Indirect Fusion to pIII Coat Proteins</title><p>An elegant way to solve the problems associated with direct N-terminal fusion of cDNA fragments to pIII was developed and introduced by Crameri and Suter in 1993. They created a new phagemid vector named pJuFo. In pJuFo, they inserted the leucine zipper domains of two transcription factors, c-Jun and c-Fos. The Jun segment was linked to the N-terminus of the truncated pIII gene, and the Fos segment was linked to the N-terminus of the cDNA fragment. As the C-terminal part of the cDNA fragment is free, the stop codon does not interfere with the expression of the fusion protein. Each fusion of Jun-pIII and Fos-cDNA is separately synthesised in the bacterial cytoplasm and with an amino terminal signal sequence directed to the periplasm. There, Jun and Fos form disulfide bonds between cysteine residues, thus creating a heterodimer and indirectly enabling the linking between pIII and the displayed peptide/protein [<xref rid="B47-viruses-16-01855" ref-type="bibr">47</xref>] (<xref rid="viruses-16-01855-f003" ref-type="fig">Figure 3</xref>). Phages that contain cDNA fragments cloned in the wrong reading frame or a premature stop codon will present short, unnatural peptides/proteins and will in most cases be lost during affinity selection [<xref rid="B43-viruses-16-01855" ref-type="bibr">43</xref>].</p><p>The pJuFo system is by far the most widely exploited system for the phage display of cDNA libraries. It was shown that it enables the display of antigens in their natural conformation and retains the activity of enzymes [<xref rid="B47-viruses-16-01855" ref-type="bibr">47</xref>,<xref rid="B48-viruses-16-01855" ref-type="bibr">48</xref>,<xref rid="B49-viruses-16-01855" ref-type="bibr">49</xref>]. Apart from being used for the identification of new IgE-binding molecules for different allergens [<xref rid="B50-viruses-16-01855" ref-type="bibr">50</xref>,<xref rid="B51-viruses-16-01855" ref-type="bibr">51</xref>,<xref rid="B52-viruses-16-01855" ref-type="bibr">52</xref>,<xref rid="B53-viruses-16-01855" ref-type="bibr">53</xref>,<xref rid="B54-viruses-16-01855" ref-type="bibr">54</xref>,<xref rid="B55-viruses-16-01855" ref-type="bibr">55</xref>], it is also utilised for the identification of new antigens in autoimmune diseases [<xref rid="B56-viruses-16-01855" ref-type="bibr">56</xref>,<xref rid="B57-viruses-16-01855" ref-type="bibr">57</xref>] and cancer [<xref rid="B58-viruses-16-01855" ref-type="bibr">58</xref>]. Cloning a wide repertoire of cDNA libraries prepared from prostate cancer biopsy samples into the pJuFo phage vector and further immunoscreening with patient serum [<xref rid="B58-viruses-16-01855" ref-type="bibr">58</xref>] have allowed for the identification of novel immunodominant cancer antigens in medicine which could be used as prognostic markers and new anti-cancer vaccine components. These antigens can be divided into tumour-associated antigens (TAAs) or tumour-specific antigens (TSAs) depending on whether they are unique to the malignant tissue (TSAs) or expressed to a varying extent on non-malignant cells (TAAs) [<xref rid="B59-viruses-16-01855" ref-type="bibr">59</xref>,<xref rid="B60-viruses-16-01855" ref-type="bibr">60</xref>]. With this approach, however, challenges may arise. Patients&#x02019; sera contain a heterogeneous antibody population with tumor-specific antibodies that differ in their affinities for antigens, mixed with tumour-unrelated antibodies that can interfere with the affinity selection process. Also, cDNA-encoded peptides/proteins are displayed on the phage with varying success [<xref rid="B58-viruses-16-01855" ref-type="bibr">58</xref>]. Hence, one must note these shortcomings when evaluating the results, as the phage-displayed peptides derived from frequently represented mRNA at the time of the cDNA library construction have a selective advantage over peptides derived from rare mRNAs. Also, fewer immunogenic tumour peptides may be lost during repeated rounds of immunoselection, resulting in bias in the phage clone selection and reduced diversity in the repertoire of the selected clones [<xref rid="B18-viruses-16-01855" ref-type="bibr">18</xref>].</p><p>It remains to be seen to what extent developments in novel phage display biopanning technologies for the enrichment and characterisation of all phage clones can further advance tumour antigen discovery studies.</p></sec><sec id="sec4dot2-viruses-16-01855"><title>4.2. C-Terminal Fusion to Coat Proteins pVI</title><p>Coat protein pVI is located at the same phage tip as pIII; however, it is the only protein with the N-terminus anchored into the phage capsid and the C-terminus facing outwards. Therefore, direct C-terminal fusion of the cDNA libraries is achievable, as the stop codon in the cDNA does not hinder the expression of pVI [<xref rid="B43-viruses-16-01855" ref-type="bibr">43</xref>]. Examples of research of this kind include the selection of candidate tumour antigens through the selection of immunogenic ligands from a colon tumour cDNA repertoire with polyclonal patients&#x02019; sera. However, one shortcoming is represented by the potential selection of phage clones that display IgG transcripts as a result of the infiltration of B-cell lymphocytes into the tumour mass [<xref rid="B44-viruses-16-01855" ref-type="bibr">44</xref>]. Hence, other studies have described antigen selection through immunoscreening phages displaying a colorectal cDNA library consisting of CRC cell lines. For the time being, the use of pVI fused cDNA libraries remains a rarity, as fusion proteins have a lower display rate than pJuFo-displayed proteins [<xref rid="B43-viruses-16-01855" ref-type="bibr">43</xref>].</p></sec><sec id="sec4dot3-viruses-16-01855"><title>4.3. Direct N-Terminal Fusion to Coat Proteins pIII and pVIII</title><p>To overcome the limitations concerning the naturally occurring stop codons and untranslated regions at the 3&#x02032; end of cDNA, cDNA fragments are fragmented before cloning. Unlike the full-length cDNA sequences fundamental to studies of gene function, smaller fragments are important for identifying immunogenic epitopes in cancer [<xref rid="B61-viruses-16-01855" ref-type="bibr">61</xref>].</p><p>According to the literature, after cloning cDNA fragments into vectors, only approximately 6% of the phagemids contained a complete open reading frame (ORF) fragment, indicating that the cDNA was correctly inserted in frame between the signal sequence gene and the pIII gene. Consequently, the constructed phage cDNA library comprised over 90% defective clones. Selection pressure favoured the propagation of phages with defective inserts or no inserts (&#x0201c;bald&#x0201d; or empty phages), which replicated more efficiently in bacterial hosts than those containing complete fragments. This phenomenon further complicated the affinity selection process by increasing the proportion of selected unwanted or unsuitable phage clones to 90&#x02013;99% [<xref rid="B62-viruses-16-01855" ref-type="bibr">62</xref>]. Thus, for effective phage display using cDNA libraries, it is essential to enrich for the correct ORFs while ensuring the successful display of the corresponding proteins or peptides [<xref rid="B61-viruses-16-01855" ref-type="bibr">61</xref>,<xref rid="B62-viruses-16-01855" ref-type="bibr">62</xref>,<xref rid="B63-viruses-16-01855" ref-type="bibr">63</xref>].</p><p>The enrichment of ORF fragments allows for the cloning of cDNA fragments as fusions with the beta-lactamase gene, positioned upstream of the pIII gene. This strategy ensures that only bacterial clones with phagemids containing in-frame-inserted fragments&#x02014;devoid of stop codons&#x02014;can express beta-lactamase and thus survive on selective media. As a result, cDNA libraries can achieve an ORF fragment representation ranging from 54% to 100% using this enrichment method. However, this approach necessitates the subsequent removal of the beta-lactamase gene insert following positive selection employing different mechanisms [<xref rid="B51-viruses-16-01855" ref-type="bibr">51</xref>,<xref rid="B52-viruses-16-01855" ref-type="bibr">52</xref>,<xref rid="B53-viruses-16-01855" ref-type="bibr">53</xref>].</p></sec></sec><sec id="sec5-viruses-16-01855"><title>5. General Considerations and Future Perspectives on Bacteriophages in Human Medicine</title><p>Filamentous bacteriophages serve as a valuable tool in immunotherapy for the identification of novel antigens or vaccine development [<xref rid="B24-viruses-16-01855" ref-type="bibr">24</xref>]. They are characterised by their small size, intrinsic immunogenicity, stability over a range of pH values and resistance to hydrolytic enzymes [<xref rid="B64-viruses-16-01855" ref-type="bibr">64</xref>]. As a consequence of their negligible tropism for mammalian cells and inability to replicate in them, coupled with their low toxicity even to the intestinal microbiome, these phages are safe for use in medicine. Phage propagation uses a prokaryotic host, which makes the production and purification of vaccines or the identification of new antigens rapid, technically simple and cost-effective at a large scale [<xref rid="B23-viruses-16-01855" ref-type="bibr">23</xref>].</p><p>Despite the numerous advantages of phage-based immunotherapeutic agents, the path to their use in human prophylaxis and therapy remains long and uncertain, with numerous unknowns yet to be explored. Notwithstanding the current understanding of the interactions between phages, bacteria and the human immune system [<xref rid="B65-viruses-16-01855" ref-type="bibr">65</xref>], further research is required to elucidate the effects of the additives in phage vaccines and the impact on individual health of the immune responses to phages. Further large-scale clinical trials are needed to establish their safety in humans, as are studies of the stability of the peptides displayed on these phages.</p></sec><sec sec-type="conclusions" id="sec6-viruses-16-01855"><title>6. Conclusions</title><p>In conclusion, phage display technology enables the discovery of tumor-specific antigens by enabling high-throughput screening of cDNA libraries, holding promise for advancing cancer treatment. Despite the inherent challenges in phage display systems, such as limitations in the display of certain proteins and translational inefficiencies, innovative solutions and strategic improvements continue to expand their utility. By addressing these limitations and leveraging its unique advantages, phage display technology can significantly contribute to the development of effective cancer vaccines and targeted therapies, paving the way for future breakthroughs in cancer treatment.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualisation, N.B., K.&#x00160;. and A.C.; software, N.B.; investigation, N.B.; writing (original draft preparation), N.B.; writing (review and editing), K.&#x00160;. and A.C.; visualisation, N.B.; supervision, K.&#x00160;. and A.C. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available on request from the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest. The funders had no role in the design of this study; in the collection, analyses or interpretation of the data; in the writing of the manuscript; or in the decision to publish the results.</p></notes><ref-list><title>References</title><ref id="B1-viruses-16-01855"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Esfahani</surname><given-names>K.</given-names></name>
<name><surname>Roudaia</surname><given-names>L.</given-names></name>
<name><surname>Buhlaiga</surname><given-names>N.</given-names></name>
<name><surname>Del Rincon</surname><given-names>S.V.</given-names></name>
<name><surname>Papneja</surname><given-names>N.</given-names></name>
<name><surname>Miller</surname><given-names>W.H.</given-names></name>
</person-group><article-title>A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future</article-title><source>Curr. Oncol.</source><year>2020</year><volume>27</volume><fpage>87</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.3747/co.27.5223</pub-id></element-citation></ref><ref id="B2-viruses-16-01855"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hanahan</surname><given-names>D.</given-names></name>
</person-group><article-title>Hallmarks of Cancer: New Dimensions</article-title><source>Cancer Discov.</source><year>2022</year><volume>12</volume><fpage>31</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-21-1059</pub-id><pub-id pub-id-type="pmid">35022204</pub-id>
</element-citation></ref><ref id="B3-viruses-16-01855"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>G.</given-names></name>
<name><surname>Ali</surname><given-names>S.A.</given-names></name>
<name><surname>McArdle</surname><given-names>S.E.B.</given-names></name>
<name><surname>Mian</surname><given-names>S.</given-names></name>
<name><surname>Ahmad</surname><given-names>M.</given-names></name>
<name><surname>Miles</surname><given-names>A.</given-names></name>
<name><surname>Rees</surname><given-names>R.C.</given-names></name>
</person-group><article-title>Immunity to Tumour Antigens</article-title><source>Curr. Pharm. Des.</source><year>2005</year><volume>11</volume><fpage>3501</fpage><lpage>3509</lpage><pub-id pub-id-type="doi">10.2174/138161205774414583</pub-id><pub-id pub-id-type="pmid">16248804</pub-id>
</element-citation></ref><ref id="B4-viruses-16-01855"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Fu</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
<name><surname>Wan</surname><given-names>D.</given-names></name>
<name><surname>Wei</surname><given-names>Y.</given-names></name>
<name><surname>Wei</surname><given-names>X.</given-names></name>
</person-group><article-title>Cancer Vaccines as Promising Immuno-Therapeutics: Platforms and Current Progress</article-title><source>J. Hematol. Oncol.</source><year>2022</year><volume>15</volume><fpage>28</fpage><pub-id pub-id-type="doi">10.1186/s13045-022-01247-x</pub-id><pub-id pub-id-type="pmid">35303904</pub-id>
</element-citation></ref><ref id="B5-viruses-16-01855"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krishnadas</surname><given-names>D.K.</given-names></name>
<name><surname>Bai</surname><given-names>F.</given-names></name>
<name><surname>Lucas</surname><given-names>K.G.</given-names></name>
</person-group><article-title>Cancer Testis Antigen and Immunotherapy</article-title><source>ImmunoTargets Ther.</source><year>2013</year><volume>2</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.2147/ITT.S35570</pub-id><pub-id pub-id-type="pmid">27471684</pub-id>
</element-citation></ref><ref id="B6-viruses-16-01855"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kanaseki</surname><given-names>T.</given-names></name>
<name><surname>Torigoe</surname><given-names>T.</given-names></name>
</person-group><article-title>Proteogenomics: Advances in Cancer Antigen Research</article-title><source>Immunol. Med.</source><year>2019</year><volume>42</volume><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1080/25785826.2019.1640500</pub-id><pub-id pub-id-type="pmid">31318319</pub-id>
</element-citation></ref><ref id="B7-viruses-16-01855"><label>7.</label><element-citation publication-type="gov"><article-title>Identification of Tumor Antigens with Immunopeptidomics&#x02014;PubMed</article-title><comment>Available online: <ext-link xlink:href="https://pubmed.ncbi.nlm.nih.gov/34635837/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/34635837/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-09-21">(accessed on 21 September 2022)</date-in-citation></element-citation></ref><ref id="B8-viruses-16-01855"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mersich</surname><given-names>C.</given-names></name>
<name><surname>Jungbauer</surname><given-names>A.</given-names></name>
</person-group><article-title>Generation of Bioactive Peptides by Biological Libraries</article-title><source>J. Chromatogr. B</source><year>2008</year><volume>861</volume><fpage>160</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/j.jchromb.2007.06.031</pub-id></element-citation></ref><ref id="B9-viruses-16-01855"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Minenkova</surname><given-names>O.</given-names></name>
<name><surname>Pucci</surname><given-names>A.</given-names></name>
<name><surname>Pavoni</surname><given-names>E.</given-names></name>
<name><surname>De Tomassi</surname><given-names>A.</given-names></name>
<name><surname>Fortugno</surname><given-names>P.</given-names></name>
<name><surname>Gargano</surname><given-names>N.</given-names></name>
<name><surname>Cianfriglia</surname><given-names>M.</given-names></name>
<name><surname>Barca</surname><given-names>S.</given-names></name>
<name><surname>De Placido</surname><given-names>S.</given-names></name>
<name><surname>Martignetti</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Identification of Tumor-Associated Antigens by Screening Phage-Displayed Human cDNA Libraries with Sera from Tumor Patients</article-title><source>Int. J. Cancer</source><year>2003</year><volume>106</volume><fpage>534</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1002/ijc.11269</pub-id><pub-id pub-id-type="pmid">12845649</pub-id>
</element-citation></ref><ref id="B10-viruses-16-01855"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pavoni</surname><given-names>E.</given-names></name>
<name><surname>Vaccaro</surname><given-names>P.</given-names></name>
<name><surname>Pucci</surname><given-names>A.</given-names></name>
<name><surname>Monteri&#x000f9;</surname><given-names>G.</given-names></name>
<name><surname>Beghetto</surname><given-names>E.</given-names></name>
<name><surname>Barca</surname><given-names>S.</given-names></name>
<name><surname>Dupuis</surname><given-names>M.L.</given-names></name>
<name><surname>De Pasquale Ceratti</surname><given-names>A.</given-names></name>
<name><surname>Lugini</surname><given-names>A.</given-names></name>
<name><surname>Cianfriglia</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Identification of a Panel of Tumor-Associated Antigens from Breast Carcinoma Cell Lines, Solid Tumors and Testis cDNA Libraries Displayed on Lambda Phage</article-title><source>BMC Cancer</source><year>2004</year><volume>4</volume><elocation-id>78</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2407-4-78</pub-id><pub-id pub-id-type="pmid">15541172</pub-id>
</element-citation></ref><ref id="B11-viruses-16-01855"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>G.</given-names></name>
<name><surname>Miles</surname><given-names>A.</given-names></name>
<name><surname>Line</surname><given-names>A.</given-names></name>
<name><surname>Rees</surname><given-names>R.C.</given-names></name>
</person-group><article-title>Identification of Tumour Antigens by Serological Analysis of cDNA Expression Cloning</article-title><source>Cancer Immunol. Immunother.</source><year>2004</year><volume>53</volume><fpage>139</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1007/s00262-003-0471-y</pub-id><pub-id pub-id-type="pmid">14722670</pub-id>
</element-citation></ref><ref id="B12-viruses-16-01855"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pulido</surname><given-names>J.</given-names></name>
<name><surname>Kottke</surname><given-names>T.</given-names></name>
<name><surname>Thompson</surname><given-names>J.</given-names></name>
<name><surname>Galivo</surname><given-names>F.</given-names></name>
<name><surname>Wongthida</surname><given-names>P.</given-names></name>
<name><surname>Diaz</surname><given-names>R.M.</given-names></name>
<name><surname>Rommelfanger</surname><given-names>D.</given-names></name>
<name><surname>Ilett</surname><given-names>E.</given-names></name>
<name><surname>Pease</surname><given-names>L.</given-names></name>
<name><surname>Pandha</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Using Virally Expressed Melanoma cDNA Libraries to Identify Tumor-Associated Antigens That Cure Melanoma</article-title><source>Nat. Biotechnol.</source><year>2012</year><volume>30</volume><fpage>337</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1038/nbt.2157</pub-id><pub-id pub-id-type="pmid">22426030</pub-id>
</element-citation></ref><ref id="B13-viruses-16-01855"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hess</surname><given-names>K.L.</given-names></name>
<name><surname>Jewell</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Phage Display as a Tool for Vaccine and Immunotherapy Development</article-title><source>Bioeng. Transl. Med.</source><year>2020</year><volume>5</volume><elocation-id>e10142</elocation-id><pub-id pub-id-type="doi">10.1002/btm2.10142</pub-id><pub-id pub-id-type="pmid">31989033</pub-id>
</element-citation></ref><ref id="B14-viruses-16-01855"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>G.P.</given-names></name>
</person-group><article-title>Filamentous Fusion Phage: Novel Expression Vectors That Display Cloned Antigens on the Virion Surface</article-title><source>Sci. New Ser.</source><year>1985</year><volume>228</volume><fpage>1315</fpage><lpage>1317</lpage><pub-id pub-id-type="doi">10.1126/science.4001944</pub-id><pub-id pub-id-type="pmid">4001944</pub-id>
</element-citation></ref><ref id="B15-viruses-16-01855"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peltomaa</surname><given-names>R.</given-names></name>
<name><surname>Benito-Pe&#x000f1;a</surname><given-names>E.</given-names></name>
<name><surname>Barderas</surname><given-names>R.</given-names></name>
<name><surname>Moreno-Bondi</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Phage Display in the Quest for New Selective Recognition Elements for Biosensors</article-title><source>ACS Omega</source><year>2019</year><volume>4</volume><fpage>11569</fpage><lpage>11580</lpage><pub-id pub-id-type="doi">10.1021/acsomega.9b01206</pub-id><pub-id pub-id-type="pmid">31460264</pub-id>
</element-citation></ref><ref id="B16-viruses-16-01855"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Vries</surname><given-names>C.R.</given-names></name>
<name><surname>Chen</surname><given-names>Q.</given-names></name>
<name><surname>Demirdjian</surname><given-names>S.</given-names></name>
<name><surname>Kaber</surname><given-names>G.</given-names></name>
<name><surname>Khosravi</surname><given-names>A.</given-names></name>
<name><surname>Liu</surname><given-names>D.</given-names></name>
<name><surname>Van Belleghem</surname><given-names>J.D.</given-names></name>
<name><surname>Bollyky</surname><given-names>P.L.</given-names></name>
</person-group><article-title>Phages in Vaccine Design and Immunity; Mechanisms and Mysteries</article-title><source>Curr. Opin. Biotechnol.</source><year>2021</year><volume>68</volume><fpage>160</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2020.11.002</pub-id><pub-id pub-id-type="pmid">33316575</pub-id>
</element-citation></ref><ref id="B17-viruses-16-01855"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saw</surname><given-names>P.E.</given-names></name>
<name><surname>Song</surname><given-names>E.-W.</given-names></name>
</person-group><article-title>Phage Display Screening of Therapeutic Peptide for Cancer Targeting and Therapy</article-title><source>Protein Cell</source><year>2019</year><volume>10</volume><fpage>787</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1007/s13238-019-0639-7</pub-id><pub-id pub-id-type="pmid">31140150</pub-id>
</element-citation></ref><ref id="B18-viruses-16-01855"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rhyner</surname><given-names>C.</given-names></name>
<name><surname>Kodzius</surname><given-names>R.</given-names></name>
<name><surname>Crameri</surname><given-names>R.</given-names></name>
</person-group><article-title>Direct Selection of cDNAs from Filamentous Phage Surface Display Libraries: Potential and Limitations</article-title><source>Curr. Pharm. Biotechnol.</source><year>2002</year><volume>3</volume><fpage>13</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.2174/1389201023378535</pub-id><pub-id pub-id-type="pmid">11883503</pub-id>
</element-citation></ref><ref id="B19-viruses-16-01855"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Natale</surname><given-names>P.</given-names></name>
<name><surname>Br&#x000fc;ser</surname><given-names>T.</given-names></name>
<name><surname>Driessen</surname><given-names>A.J.M.</given-names></name>
</person-group><article-title>Sec- and Tat-Mediated Protein Secretion across the Bacterial Cytoplasmic Membrane&#x02014;Distinct Translocases and Mechanisms</article-title><source>Biochim. Biophys. Acta BBA&#x02014;Biomembr.</source><year>2008</year><volume>1778</volume><fpage>1735</fpage><lpage>1756</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2007.07.015</pub-id></element-citation></ref><ref id="B20-viruses-16-01855"><label>20.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Rakonjac</surname><given-names>J.</given-names></name>
<name><surname>Russel</surname><given-names>M.</given-names></name>
<name><surname>Khanum</surname><given-names>S.</given-names></name>
<name><surname>Brooke</surname><given-names>S.J.</given-names></name>
<name><surname>Raji&#x0010d;</surname><given-names>M.</given-names></name>
</person-group><article-title>Filamentous Phage: Structure and Biology</article-title><source>Recombinant Antibodies for Infectious Diseases</source><person-group person-group-type="editor">
<name><surname>Lim</surname><given-names>T.S.</given-names></name>
</person-group><series>Advances in Experimental Medicine and Biology</series><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham, Switzerland</publisher-loc><year>2017</year><volume>Volume 1053</volume><fpage>1</fpage><lpage>20</lpage><isbn>978-3-319-72076-0</isbn></element-citation></ref><ref id="B21-viruses-16-01855"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>C&#x000e1;rcamo</surname><given-names>J.</given-names></name>
<name><surname>Ravera</surname><given-names>M.W.</given-names></name>
<name><surname>Brissette</surname><given-names>R.</given-names></name>
<name><surname>Dedova</surname><given-names>O.</given-names></name>
<name><surname>Beasley</surname><given-names>J.R.</given-names></name>
<name><surname>Alam-Mogh&#x000e9;</surname><given-names>A.</given-names></name>
<name><surname>Wan</surname><given-names>C.</given-names></name>
<name><surname>Blume</surname><given-names>A.</given-names></name>
<name><surname>Mandecki</surname><given-names>W.</given-names></name>
</person-group><article-title>Unexpected Frameshifts from Gene to Expressed Protein in a Phage-Displayed Peptide Library</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1998</year><volume>95</volume><fpage>11146</fpage><lpage>11151</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.19.11146</pub-id><pub-id pub-id-type="pmid">9736704</pub-id>
</element-citation></ref><ref id="B22-viruses-16-01855"><label>22.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Kutter</surname><given-names>E.</given-names></name>
<name><surname>Sulakvelidze</surname><given-names>A.</given-names></name>
</person-group><source>Bacteriophages&#x02014;Biology and Application</source><publisher-name>CRC Press</publisher-name><publisher-loc>Boca Raton, FL, USA</publisher-loc><year>2005</year><volume>Volume 2005</volume></element-citation></ref><ref id="B23-viruses-16-01855"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Foglizzo</surname><given-names>V.</given-names></name>
<name><surname>Marchi&#x000f2;</surname><given-names>S.</given-names></name>
</person-group><article-title>Bacteriophages as Therapeutic and Diagnostic Vehicles in Cancer</article-title><source>Pharmaceuticals</source><year>2021</year><volume>14</volume><elocation-id>161</elocation-id><pub-id pub-id-type="doi">10.3390/ph14020161</pub-id><pub-id pub-id-type="pmid">33671476</pub-id>
</element-citation></ref><ref id="B24-viruses-16-01855"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gonz&#x000e1;lez-Mora</surname><given-names>A.</given-names></name>
<name><surname>Hern&#x000e1;ndez-P&#x000e9;rez</surname><given-names>J.</given-names></name>
<name><surname>Iqbal</surname><given-names>H.M.N.</given-names></name>
<name><surname>Rito-Palomares</surname><given-names>M.</given-names></name>
<name><surname>Benavides</surname><given-names>J.</given-names></name>
</person-group><article-title>Bacteriophage-Based Vaccines: A Potent Approach for Antigen Delivery</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><elocation-id>504</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8030504</pub-id><pub-id pub-id-type="pmid">32899720</pub-id>
</element-citation></ref><ref id="B25-viruses-16-01855"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sartorius</surname><given-names>R.</given-names></name>
<name><surname>D&#x02019;Apice</surname><given-names>L.</given-names></name>
<name><surname>Prisco</surname><given-names>A.</given-names></name>
<name><surname>De Berardinis</surname><given-names>P.</given-names></name>
</person-group><article-title>Arming Filamentous Bacteriophage, a Nature-Made Nanoparticle, for New Vaccine and Immunotherapeutic Strategies</article-title><source>Pharmaceutics</source><year>2019</year><volume>11</volume><elocation-id>437</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics11090437</pub-id><pub-id pub-id-type="pmid">31480551</pub-id>
</element-citation></ref><ref id="B26-viruses-16-01855"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ebrahimizadeh</surname><given-names>W.</given-names></name>
<name><surname>Rajabibazl</surname><given-names>M.</given-names></name>
</person-group><article-title>Bacteriophage Vehicles for Phage Display: Biology, Mechanism, and Application</article-title><source>Curr. Microbiol.</source><year>2014</year><volume>69</volume><fpage>109</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1007/s00284-014-0557-0</pub-id><pub-id pub-id-type="pmid">24638925</pub-id>
</element-citation></ref><ref id="B27-viruses-16-01855"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qi</surname><given-names>H.</given-names></name>
<name><surname>Lu</surname><given-names>H.</given-names></name>
<name><surname>Qiu</surname><given-names>H.-J.</given-names></name>
<name><surname>Petrenko</surname><given-names>V.</given-names></name>
<name><surname>Liu</surname><given-names>A.</given-names></name>
</person-group><article-title>Phagemid Vectors for Phage Display: Properties, Characteristics and Construction</article-title><source>J. Mol. Biol.</source><year>2012</year><volume>417</volume><fpage>129</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2012.01.038</pub-id><pub-id pub-id-type="pmid">22310045</pub-id>
</element-citation></ref><ref id="B28-viruses-16-01855"><label>28.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Moreno-Palanques</surname><given-names>R.F.</given-names></name>
<name><surname>Fuldner</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Construction of cDNA Libraries</article-title><source>Automated DNA Sequencing and Analysis</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>1994</year><fpage>102</fpage><lpage>109</lpage><isbn>978-0-08-092639-1</isbn></element-citation></ref><ref id="B29-viruses-16-01855"><label>29.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Lodish</surname><given-names>H.</given-names></name>
<name><surname>Berk</surname><given-names>A.</given-names></name>
<name><surname>Zipursky</surname><given-names>S.L.</given-names></name>
<name><surname>Matsudaira</surname><given-names>P.</given-names></name>
<name><surname>Baltimore</surname><given-names>D.</given-names></name>
<name><surname>Darnell</surname><given-names>J.</given-names></name>
</person-group><article-title>Constructing DNA Libraries with &#x003bb; Phage and Other Cloning Vectors</article-title><source>Molecular Cell Biology</source><edition>4th ed.</edition><publisher-name>WH Freeman</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2000</year></element-citation></ref><ref id="B30-viruses-16-01855"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferreira</surname><given-names>A.</given-names></name>
<name><surname>Lamy</surname><given-names>M.</given-names></name>
<name><surname>Margarida Rocha</surname><given-names>M.</given-names></name>
<name><surname>Silva</surname><given-names>G.</given-names></name>
<name><surname>Bandeiras</surname><given-names>T.M.</given-names></name>
<name><surname>Barbas</surname><given-names>A.</given-names></name>
</person-group><article-title>Production and Characterization of a Novel Delta-like 1 Functional Unit as a Tool for Notch Pathway Activation and Generation of a Specific Antibody</article-title><source>Protein Expr. Purif.</source><year>2018</year><volume>146</volume><fpage>8</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.pep.2018.01.008</pub-id><pub-id pub-id-type="pmid">29366964</pub-id>
</element-citation></ref><ref id="B31-viruses-16-01855"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ayo</surname><given-names>A.</given-names></name>
<name><surname>Laakkonen</surname><given-names>P.</given-names></name>
</person-group><article-title>Peptide-Based Strategies for Targeted Tumor Treatment and Imaging</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>481</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13040481</pub-id><pub-id pub-id-type="pmid">33918106</pub-id>
</element-citation></ref><ref id="B32-viruses-16-01855"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pung</surname><given-names>H.S.</given-names></name>
<name><surname>Tye</surname><given-names>G.J.</given-names></name>
<name><surname>Leow</surname><given-names>C.H.</given-names></name>
<name><surname>Ng</surname><given-names>W.K.</given-names></name>
<name><surname>Lai</surname><given-names>N.S.</given-names></name>
</person-group><article-title>Generation of Peptides Using Phage Display Technology for Cancer Diagnosis and Molecular Imaging</article-title><source>Mol. Biol. Rep.</source><year>2023</year><volume>50</volume><fpage>4653</fpage><lpage>4664</lpage><pub-id pub-id-type="doi">10.1007/s11033-023-08380-x</pub-id><pub-id pub-id-type="pmid">37014570</pub-id>
</element-citation></ref><ref id="B33-viruses-16-01855"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>D.</given-names></name>
<name><surname>Huang</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Zhu</surname><given-names>M.</given-names></name>
<name><surname>Feng</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Lu</surname><given-names>S.</given-names></name>
<name><surname>He</surname><given-names>S.</given-names></name>
</person-group><article-title>Screening and Identification of a CD44v6 Specific Peptide Using Improved Phage Display for Gastric Cancer Targeting</article-title><source>Ann. Transl. Med.</source><year>2020</year><volume>8</volume><fpage>1442</fpage><pub-id pub-id-type="doi">10.21037/atm-19-4781</pub-id><pub-id pub-id-type="pmid">33313187</pub-id>
</element-citation></ref><ref id="B34-viruses-16-01855"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matsuo</surname><given-names>A.L.</given-names></name>
<name><surname>Juliano</surname><given-names>M.A.</given-names></name>
<name><surname>Figueiredo</surname><given-names>C.R.</given-names></name>
<name><surname>Batista</surname><given-names>W.L.</given-names></name>
<name><surname>Tanaka</surname><given-names>A.S.</given-names></name>
<name><surname>Travassos</surname><given-names>L.R.</given-names></name>
</person-group><article-title>A New Phage-Display Tumor-Homing Peptide Fused to Antiangiogenic Peptide Generates a Novel Bioactive Molecule with Antimelanoma Activity</article-title><source>Mol. Cancer Res.</source><year>2011</year><volume>9</volume><fpage>1471</fpage><lpage>1478</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-10-0501</pub-id><pub-id pub-id-type="pmid">21900362</pub-id>
</element-citation></ref><ref id="B35-viruses-16-01855"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shoae-Hassani</surname><given-names>A.</given-names></name>
<name><surname>Mortazavi-Tabatabaei</surname><given-names>S.A.</given-names></name>
<name><surname>Sharif</surname><given-names>S.</given-names></name>
<name><surname>Madadi</surname><given-names>S.</given-names></name>
<name><surname>Rezaei-Khaligh</surname><given-names>H.</given-names></name>
<name><surname>Verdi</surname><given-names>J.</given-names></name>
</person-group><article-title>Recombinant &#x003bb; Bacteriophage Displaying Nanobody towards Third Domain of HER-2 Epitope Inhibits Proliferation of Breast Carcinoma SKBR-3 Cell Line</article-title><source>Arch. Immunol. Ther. Exp.</source><year>2013</year><volume>61</volume><fpage>75</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1007/s00005-012-0206-x</pub-id></element-citation></ref><ref id="B36-viruses-16-01855"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yau</surname><given-names>A.W.N.</given-names></name>
<name><surname>Chu</surname><given-names>S.Y.C.</given-names></name>
<name><surname>Yap</surname><given-names>W.H.</given-names></name>
<name><surname>Wong</surname><given-names>C.L.</given-names></name>
<name><surname>Chia</surname><given-names>A.Y.Y.</given-names></name>
<name><surname>Tang</surname><given-names>Y.-Q.</given-names></name>
</person-group><article-title>Phage Display Screening in Breast Cancer: From Peptide Discovery to Clinical Applications</article-title><source>Life Sci.</source><year>2024</year><volume>357</volume><fpage>123077</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2024.123077</pub-id><pub-id pub-id-type="pmid">39332485</pub-id>
</element-citation></ref><ref id="B37-viruses-16-01855"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>T.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
</person-group><article-title>Monoclonal Antibody Development for Cancer Treatment Using the Phage Display Library Platform</article-title><source>Biologics</source><year>2024</year><volume>4</volume><fpage>55</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.3390/biologics4010005</pub-id></element-citation></ref><ref id="B38-viruses-16-01855"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aghebati-Maleki</surname><given-names>L.</given-names></name>
<name><surname>Bakhshinejad</surname><given-names>B.</given-names></name>
<name><surname>Baradaran</surname><given-names>B.</given-names></name>
<name><surname>Motallebnezhad</surname><given-names>M.</given-names></name>
<name><surname>Aghebati-Maleki</surname><given-names>A.</given-names></name>
<name><surname>Nickho</surname><given-names>H.</given-names></name>
<name><surname>Yousefi</surname><given-names>M.</given-names></name>
<name><surname>Majidi</surname><given-names>J.</given-names></name>
</person-group><article-title>Phage Display as a Promising Approach for Vaccine Development</article-title><source>J. Biomed. Sci.</source><year>2016</year><volume>23</volume><elocation-id>66</elocation-id><pub-id pub-id-type="doi">10.1186/s12929-016-0285-9</pub-id><pub-id pub-id-type="pmid">27680328</pub-id>
</element-citation></ref><ref id="B39-viruses-16-01855"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brown</surname><given-names>K.C.</given-names></name>
</person-group><article-title>Peptidic Tumor Targeting Agents: The Road from Phage Display Peptide Selections to Clinical Applications</article-title><source>Curr. Pharm. Des.</source><year>2010</year><volume>16</volume><fpage>1040</fpage><lpage>1054</lpage><pub-id pub-id-type="doi">10.2174/138161210790963788</pub-id><pub-id pub-id-type="pmid">20030617</pub-id>
</element-citation></ref><ref id="B40-viruses-16-01855"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nemudraya</surname><given-names>A.A.</given-names></name>
<name><surname>Richter</surname><given-names>V.A.</given-names></name>
<name><surname>Kuligina</surname><given-names>E.V.</given-names></name>
</person-group><article-title>Phage Peptide Libraries As a Source of Targeted Ligands</article-title><source>Acta Nat.</source><year>2016</year><volume>8</volume><fpage>48</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.32607/20758251-2016-8-1-48-57</pub-id></element-citation></ref><ref id="B41-viruses-16-01855"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arap</surname><given-names>W.</given-names></name>
<name><surname>Kolonin</surname><given-names>M.G.</given-names></name>
<name><surname>Trepel</surname><given-names>M.</given-names></name>
<name><surname>Lahdenranta</surname><given-names>J.</given-names></name>
<name><surname>Card&#x000f3;-Vila</surname><given-names>M.</given-names></name>
<name><surname>Giordano</surname><given-names>R.J.</given-names></name>
<name><surname>Mintz</surname><given-names>P.J.</given-names></name>
<name><surname>Ardelt</surname><given-names>P.U.</given-names></name>
<name><surname>Yao</surname><given-names>V.J.</given-names></name>
<name><surname>Vidal</surname><given-names>C.I.</given-names></name>
<etal/>
</person-group><article-title>Steps toward Mapping the Human Vasculature by Phage Display</article-title><source>Nat. Med.</source><year>2002</year><volume>8</volume><fpage>121</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1038/nm0202-121</pub-id><pub-id pub-id-type="pmid">11821895</pub-id>
</element-citation></ref><ref id="B42-viruses-16-01855"><label>42.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Barbas</surname><given-names>C.F.</given-names><suffix>III</suffix></name>
<name><surname>Burton</surname><given-names>D.R.</given-names></name>
<name><surname>Scott</surname><given-names>J.K.</given-names></name>
<name><surname>Silverman</surname><given-names>G.J.</given-names></name>
</person-group><source>Phage Display: A Laboratory Manual</source><publisher-name>Cold Spring Harbor Laboratory Press</publisher-name><publisher-loc>Long Island, NY, USA</publisher-loc><year>2001</year></element-citation></ref><ref id="B43-viruses-16-01855"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Georgieva</surname><given-names>Y.</given-names></name>
<name><surname>Konthur</surname><given-names>Z.</given-names></name>
</person-group><article-title>Design and Screening of M13 Phage Display cDNA Libraries</article-title><source>Molecules</source><year>2011</year><volume>16</volume><fpage>1667</fpage><lpage>1681</lpage><pub-id pub-id-type="doi">10.3390/molecules16021667</pub-id><pub-id pub-id-type="pmid">21330956</pub-id>
</element-citation></ref><ref id="B44-viruses-16-01855"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hufton</surname><given-names>S.E.</given-names></name>
<name><surname>Moerkerk</surname><given-names>P.T.</given-names></name>
<name><surname>Meulemans</surname><given-names>E.V.</given-names></name>
<name><surname>de Bru&#x000ef;ne</surname><given-names>A.</given-names></name>
<name><surname>Arends</surname><given-names>J.-W.</given-names></name>
<name><surname>Hoogenboom</surname><given-names>H.R.</given-names></name>
</person-group><article-title>Phage Display of cDNA Repertoires: The pVI Display System and Its Applications for the Selection of Immunogenic Ligands</article-title><source>J. Immunol. Methods</source><year>1999</year><volume>231</volume><fpage>39</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/S0022-1759(99)00139-8</pub-id><pub-id pub-id-type="pmid">10648926</pub-id>
</element-citation></ref><ref id="B45-viruses-16-01855"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jestin</surname><given-names>J.-L.</given-names></name>
<name><surname>Volioti</surname><given-names>G.</given-names></name>
<name><surname>Winter</surname><given-names>G.</given-names></name>
</person-group><article-title>Improving the Display of Proteins on Filamentous Phage</article-title><source>Res. Microbiol.</source><year>2001</year><volume>152</volume><fpage>187</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1016/S0923-2508(01)01191-3</pub-id><pub-id pub-id-type="pmid">11316373</pub-id>
</element-citation></ref><ref id="B46-viruses-16-01855"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bothmann</surname><given-names>H.</given-names></name>
<name><surname>Pl&#x000fc;ckthun</surname><given-names>A.</given-names></name>
</person-group><article-title>Selection for a Periplasmic Factor Improving Phage Display and Functional Periplasmic Expression</article-title><source>Nat. Biotechnol.</source><year>1998</year><volume>16</volume><fpage>376</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1038/nbt0498-376</pub-id><pub-id pub-id-type="pmid">9555730</pub-id>
</element-citation></ref><ref id="B47-viruses-16-01855"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crameri</surname><given-names>R.</given-names></name>
<name><surname>Suter</surname><given-names>M.</given-names></name>
</person-group><article-title>Display of Biologically Active Proteins on the Surface of Filamentous Phages: A cDNA Cloning System for Selection of Functional Gene Products Linked to the Genetic Information Responsible for Their Production</article-title><source>Gene</source><year>1993</year><volume>137</volume><fpage>69</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/0378-1119(93)90253-Y</pub-id><pub-id pub-id-type="pmid">8282202</pub-id>
</element-citation></ref><ref id="B48-viruses-16-01855"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crameri</surname><given-names>R.</given-names></name>
<name><surname>Jaussi</surname><given-names>R.</given-names></name>
<name><surname>Menz</surname><given-names>G.</given-names></name>
<name><surname>Blaser</surname><given-names>K.</given-names></name>
</person-group><article-title>Display of Expression Products of cDNA Libraries on Phage Surfaces</article-title><source>Eur. J. Biochem.</source><year>1994</year><volume>226</volume><fpage>53</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1111/j.1432-1033.1994.00t53.x</pub-id><pub-id pub-id-type="pmid">7957259</pub-id>
</element-citation></ref><ref id="B49-viruses-16-01855"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weichel</surname><given-names>M.</given-names></name>
<name><surname>Jaussi</surname><given-names>R.</given-names></name>
<name><surname>Rhyner</surname><given-names>C.</given-names></name>
<name><surname>Crameri</surname><given-names>R.</given-names></name>
</person-group><article-title>Display of <italic toggle="yes">E. coli</italic> Alkaline Phosphatase pIII or pVIII Fusions on Phagemid Surfaces Reveals Monovalent Decoration with Active Molecules</article-title><source>Open Biochem. J.</source><year>2008</year><volume>2</volume><fpage>38</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.2174/1874091X00802010038</pub-id><pub-id pub-id-type="pmid">18949073</pub-id>
</element-citation></ref><ref id="B50-viruses-16-01855"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brander</surname><given-names>K.A.</given-names></name>
<name><surname>Borb&#x000e9;ly</surname><given-names>P.</given-names></name>
<name><surname>Crameri</surname><given-names>R.</given-names></name>
<name><surname>Pichler</surname><given-names>W.J.</given-names></name>
<name><surname>Helbling</surname><given-names>A.</given-names></name>
</person-group><article-title>IgE-Binding Proliferative Responses and Skin Test Reactivity to Cop c 1, the First Recombinant Allergen from the Basidiomycete Coprinus Comatus</article-title><source>J. Allergy Clin. Immunol.</source><year>1999</year><volume>104</volume><fpage>630</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1016/S0091-6749(99)70335-0</pub-id><pub-id pub-id-type="pmid">10482839</pub-id>
</element-citation></ref><ref id="B51-viruses-16-01855"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crameri</surname><given-names>R.</given-names></name>
<name><surname>Kodzius</surname><given-names>R.</given-names></name>
<name><surname>Konthur</surname><given-names>Z.</given-names></name>
<name><surname>Lehrach</surname><given-names>H.</given-names></name>
<name><surname>Blaser</surname><given-names>K.</given-names></name>
<name><surname>Walter</surname><given-names>G.</given-names></name>
</person-group><article-title>Tapping Allergen Repertoires by Advanced Cloning Technologies</article-title><source>Int. Arch. Allergy Immunol.</source><year>2001</year><volume>124</volume><fpage>43</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1159/000053664</pub-id><pub-id pub-id-type="pmid">11306922</pub-id>
</element-citation></ref><ref id="B52-viruses-16-01855"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kodzius</surname><given-names>R.</given-names></name>
<name><surname>Rhyner</surname><given-names>C.</given-names></name>
<name><surname>Konthur</surname><given-names>Z.</given-names></name>
<name><surname>Buczek</surname><given-names>D.</given-names></name>
<name><surname>Lehrach</surname><given-names>H.</given-names></name>
<name><surname>Walter</surname><given-names>G.</given-names></name>
<name><surname>Crameri</surname><given-names>R.</given-names></name>
</person-group><article-title>Rapid Identification of Allergen-Encoding cDNA Clones by Phage Display and High-Density Arrays</article-title><source>Comb. Chem. High Throughput Screen.</source><year>2003</year><volume>6</volume><fpage>147</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.2174/1386207033329751</pub-id><pub-id pub-id-type="pmid">12678710</pub-id>
</element-citation></ref><ref id="B53-viruses-16-01855"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eriksson</surname><given-names>T.L.J.</given-names></name>
<name><surname>Rasool</surname><given-names>O.</given-names></name>
<name><surname>Huecas</surname><given-names>S.</given-names></name>
<name><surname>Whitley</surname><given-names>P.</given-names></name>
<name><surname>Crameri</surname><given-names>R.</given-names></name>
<name><surname>Appenzeller</surname><given-names>U.</given-names></name>
<name><surname>Gafvelin</surname><given-names>G.</given-names></name>
<name><surname>van Hage-Hamsten</surname><given-names>M.</given-names></name>
</person-group><article-title>Cloning of Three New Allergens from the Dust Mite <italic toggle="yes">Lepidoglyphus destructor</italic> Using Phage Surface Display Technology: Cloning of <italic toggle="yes">L. destructor</italic> Allergens Using Phage Display</article-title><source>Eur. J. Biochem.</source><year>2001</year><volume>268</volume><fpage>287</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1046/j.1432-1327.2001.01879.x</pub-id><pub-id pub-id-type="pmid">11168362</pub-id>
</element-citation></ref><ref id="B54-viruses-16-01855"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kleber-Janke</surname><given-names>T.</given-names></name>
<name><surname>Crameri</surname><given-names>R.</given-names></name>
<name><surname>Scheurer</surname><given-names>S.</given-names></name>
<name><surname>Vieths</surname><given-names>S.</given-names></name>
<name><surname>Becker</surname><given-names>W.-M.</given-names></name>
</person-group><article-title>Patient-Tailored Cloning of Allergens by Phage Display: Peanut (<italic toggle="yes">Arachis hypogaea</italic>) Profilin, a Food Allergen Derived from a Rare mRNA</article-title><source>J. Chromatogr. B. Biomed. Sci. App.</source><year>2001</year><volume>756</volume><fpage>295</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1016/S0378-4347(01)00088-3</pub-id><pub-id pub-id-type="pmid">11419720</pub-id>
</element-citation></ref><ref id="B55-viruses-16-01855"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bittner</surname><given-names>C.</given-names></name>
<name><surname>Grassau</surname><given-names>B.</given-names></name>
<name><surname>Frenzel</surname><given-names>K.</given-names></name>
<name><surname>Baur</surname><given-names>X.</given-names></name>
</person-group><article-title>Identification of Wheat Gliadins as an Allergen Family Related to Baker&#x02019;s Asthma</article-title><source>J. Allergy Clin. Immunol.</source><year>2008</year><volume>121</volume><fpage>744</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2007.09.051</pub-id><pub-id pub-id-type="pmid">18036646</pub-id>
</element-citation></ref><ref id="B56-viruses-16-01855"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kemp</surname><given-names>E.H.</given-names></name>
<name><surname>Herd</surname><given-names>L.M.</given-names></name>
<name><surname>Waterman</surname><given-names>E.A.</given-names></name>
<name><surname>Wilson</surname><given-names>A.G.</given-names></name>
<name><surname>Weetman</surname><given-names>A.P.</given-names></name>
<name><surname>Watson</surname><given-names>P.F.</given-names></name>
</person-group><article-title>Immunoscreening of Phage-Displayed cDNA-Encoded Polypeptides Identifies B Cell Targets in Autoimmune Diseaseq</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2002</year><volume>9</volume><fpage>169</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/S0006-291X(02)02421-X</pub-id></element-citation></ref><ref id="B57-viruses-16-01855"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Waterman</surname><given-names>E.A.</given-names></name>
<name><surname>Gawkrodger</surname><given-names>D.J.</given-names></name>
<name><surname>Watson</surname><given-names>P.F.</given-names></name>
<name><surname>Weetman</surname><given-names>A.P.</given-names></name>
<name><surname>Helen Kemp</surname><given-names>E.</given-names></name>
</person-group><article-title>Autoantigens in Vitiligo Identified by the Serological Selection of a Phage-Displayed Melanocyte cDNA Expression Library</article-title><source>J. Investig. Dermatol.</source><year>2010</year><volume>130</volume><fpage>230</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1038/jid.2009.207</pub-id><pub-id pub-id-type="pmid">19587696</pub-id>
</element-citation></ref><ref id="B58-viruses-16-01855"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Foss&#x000e5;</surname><given-names>A.</given-names></name>
<name><surname>Als&#x000f8;e</surname><given-names>L.</given-names></name>
<name><surname>Crameri</surname><given-names>R.</given-names></name>
<name><surname>Funderud</surname><given-names>S.</given-names></name>
<name><surname>Gaudernack</surname><given-names>G.</given-names></name>
<name><surname>Smeland</surname><given-names>E.B.</given-names></name>
</person-group><article-title>Serological Cloning of Cancer/Testis Antigens Expressed in Prostate Cancer Using cDNA Phage Surface Display</article-title><source>Cancer Immunol. Immunother.</source><year>2004</year><volume>53</volume><fpage>431</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1007/s00262-003-0458-8</pub-id><pub-id pub-id-type="pmid">14747957</pub-id>
</element-citation></ref><ref id="B59-viruses-16-01855"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pitcovski</surname><given-names>J.</given-names></name>
<name><surname>Shahar</surname><given-names>E.</given-names></name>
<name><surname>Aizenshtein</surname><given-names>E.</given-names></name>
<name><surname>Gorodetsky</surname><given-names>R.</given-names></name>
</person-group><article-title>Melanoma Antigens and Related Immunological Markers</article-title><source>Crit. Rev. Oncol. Hematol.</source><year>2017</year><volume>115</volume><fpage>36</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2017.05.001</pub-id><pub-id pub-id-type="pmid">28602168</pub-id>
</element-citation></ref><ref id="B60-viruses-16-01855"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rezaei</surname><given-names>T.</given-names></name>
<name><surname>Davoudian</surname><given-names>E.</given-names></name>
<name><surname>Khalili</surname><given-names>S.</given-names></name>
<name><surname>Amini</surname><given-names>M.</given-names></name>
<name><surname>Hejazi</surname><given-names>M.</given-names></name>
<name><surname>de la Guardia</surname><given-names>M.</given-names></name>
<name><surname>Mokhtarzadeh</surname><given-names>A.</given-names></name>
</person-group><article-title>Strategies in DNA Vaccine for Melanoma Cancer</article-title><source>Pigment Cell Melanoma Res.</source><year>2020</year><volume>34</volume><fpage>869</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1111/pcmr.12933</pub-id><pub-id pub-id-type="pmid">33089665</pub-id>
</element-citation></ref><ref id="B61-viruses-16-01855"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zacchi</surname><given-names>P.</given-names></name>
<name><surname>Sblattero</surname><given-names>D.</given-names></name>
<name><surname>Florian</surname><given-names>F.</given-names></name>
<name><surname>Marzari</surname><given-names>R.</given-names></name>
<name><surname>Bradbury</surname><given-names>A.R.M.</given-names></name>
</person-group><article-title>Selecting Open Reading Frames From DNA</article-title><source>Genome Res.</source><year>2003</year><volume>13</volume><fpage>980</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1101/gr.861503</pub-id><pub-id pub-id-type="pmid">12727911</pub-id>
</element-citation></ref><ref id="B62-viruses-16-01855"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hust</surname><given-names>M.</given-names></name>
<name><surname>Meysing</surname><given-names>M.</given-names></name>
<name><surname>Schirrmann</surname><given-names>T.</given-names></name>
<name><surname>Selke</surname><given-names>M.</given-names></name>
<name><surname>Meens</surname><given-names>J.</given-names></name>
<name><surname>Gerlach</surname><given-names>G.-F.</given-names></name>
<name><surname>D&#x000fc;bel</surname><given-names>S.</given-names></name>
</person-group><article-title>Enrichment of Open Reading Frames Presented on Bacteriophage M13 Using Hyperphage</article-title><source>BioTechniques</source><year>2006</year><volume>41</volume><fpage>335</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.2144/000112225</pub-id><pub-id pub-id-type="pmid">16989094</pub-id>
</element-citation></ref><ref id="B63-viruses-16-01855"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Faix</surname><given-names>P.H.</given-names></name>
<name><surname>Burg</surname><given-names>M.A.</given-names></name>
<name><surname>Gonzales</surname><given-names>M.</given-names></name>
<name><surname>Ravey</surname><given-names>E.P.</given-names></name>
<name><surname>Baird</surname><given-names>A.</given-names></name>
<name><surname>Larocca</surname><given-names>D.</given-names></name>
</person-group><article-title>Phage Display of cDNA Libraries: Enrichment of cDNA Expression Using Open Reading Frame Selection</article-title><source>BioTechniques</source><year>2004</year><volume>36</volume><fpage>1018</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.2144/04366RR03</pub-id><pub-id pub-id-type="pmid">15211753</pub-id>
</element-citation></ref><ref id="B64-viruses-16-01855"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Namdee</surname><given-names>K.</given-names></name>
<name><surname>Khongkow</surname><given-names>M.</given-names></name>
<name><surname>Boonrungsiman</surname><given-names>S.</given-names></name>
<name><surname>Nittayasut</surname><given-names>N.</given-names></name>
<name><surname>Asavarut</surname><given-names>P.</given-names></name>
<name><surname>Temisak</surname><given-names>S.</given-names></name>
<name><surname>Saengkrit</surname><given-names>N.</given-names></name>
<name><surname>Puttipipatkhachorn</surname><given-names>S.</given-names></name>
<name><surname>Hajitou</surname><given-names>A.</given-names></name>
<name><surname>Ruxrungtham</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Thermoresponsive Bacteriophage Nanocarrier as a Gene Delivery Vector Targeted to the Gastrointestinal Tract</article-title><source>Mol. Ther. Nucleic Acids</source><year>2018</year><volume>12</volume><fpage>33</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2018.04.012</pub-id><pub-id pub-id-type="pmid">30195771</pub-id>
</element-citation></ref><ref id="B65-viruses-16-01855"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van Belleghem</surname><given-names>J.</given-names></name>
<name><surname>D&#x00105;browska</surname><given-names>K.</given-names></name>
<name><surname>Vaneechoutte</surname><given-names>M.</given-names></name>
<name><surname>Barr</surname><given-names>J.</given-names></name>
<name><surname>Bollyky</surname><given-names>P.</given-names></name>
</person-group><article-title>Interactions between Bacteriophage, Bacteria, and the Mammalian Immune System</article-title><source>Viruses</source><year>2018</year><volume>11</volume><elocation-id>10</elocation-id><pub-id pub-id-type="doi">10.3390/v11010010</pub-id><pub-id pub-id-type="pmid">30585199</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-16-01855-f001"><label>Figure 1</label><caption><p>Schematic representation of the construction of cDNA libraries and their display on filamentous bacteriophages.</p></caption><graphic xlink:href="viruses-16-01855-g001" position="float"/></fig><fig position="float" id="viruses-16-01855-f002"><label>Figure 2</label><caption><p>Schematic of an affinity-driven process in which phage-displayed libraries are screened against a variety of targets and target-specific phage-displayed (poly)peptides (e.g., novel cancer ligands) are subsequently identified.</p></caption><graphic xlink:href="viruses-16-01855-g002" position="float"/></fig><fig position="float" id="viruses-16-01855-f003"><label>Figure 3</label><caption><p>Indirect fusion to pIII coat proteins. Adapted from [<xref rid="B47-viruses-16-01855" ref-type="bibr">47</xref>].</p></caption><graphic xlink:href="viruses-16-01855-g003" position="float"/></fig></floats-group></article>